Targeted Medical Pharma, Inc. (OTCQB:TRGM) is a publicly traded, Los Angeles-based biotechnology company that develops amino acid based medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders.
The Company manufactures 10 proprietary amino acid based medical foods, and the dietary supplements GABADone™ Advanced and Clearwayz™. Each product uses Targeted Cellular Technology, the Company's patented micro-nutrient delivery system that improves the absorption and cellular utilization of amino acids, nutrients and neurotransmitters. The products are manufactured in the United States and sold directly to physicians, pharmacies and patients in the United States, Japan and China.
The Company is seeking partners interested in licensing the Company’s core ingredient technology to develop pharmacologic, amino acid and nutrient based therapies for a variety of chronic diseases that current therapies have been unable to address effectively and safely.
The Company is committed to delivering long-term value to investors by maintaining disciplined cost controls, optimizing capital investment and adhering to the highest standards of corporate governance.